Incyte (NASDAQ:INCY) Stock Price Expected to Rise, HC Wainwright Analyst Says

Incyte (NASDAQ:INCY) had its price objective upped by research analysts at HC Wainwright from $140.00 to $150.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 15.45% from the stock’s current price.

INCY has been the topic of several other reports. Royal Bank Of Canada upped their price objective on Incyte from $95.00 to $99.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. Citigroup reaffirmed a “market perform” rating on shares of Incyte in a research note on Wednesday, July 15th. Oppenheimer reiterated a “market perform” rating and issued a $120.00 price target on shares of Incyte in a research report on Tuesday. Sanford C. Bernstein assumed coverage on Incyte in a report on Thursday, May 21st. They set a “market perform” rating and a $99.00 price objective for the company. Finally, TD Cowen restated a “hold” rating on shares of Incyte in a research note on Tuesday, June 9th. Eight research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $113.60.

Incyte Price Performance

Shares of Incyte stock opened at $129.93 on Wednesday. The firm has a market cap of $25.96 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 1.03 and a beta of 0.76. The firm’s 50-day simple moving average is $107.99 and its 200-day simple moving average is $101.86. Incyte has a twelve month low of $71.00 and a twelve month high of $132.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.60 and a current ratio of 3.68.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.20 by $0.89. The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.50 billion. Incyte had a net margin of 26.71% and a return on equity of 26.66%. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.57 earnings per share. As a group, research analysts expect that Incyte will post 6.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Incyte

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of Incyte by 11.3% during the fourth quarter. Geode Capital Management LLC now owns 4,993,012 shares of the biopharmaceutical company’s stock worth $491,500,000 after purchasing an additional 506,842 shares in the last quarter. Invesco Ltd. raised its holdings in Incyte by 13.2% during the 4th quarter. Invesco Ltd. now owns 3,473,781 shares of the biopharmaceutical company’s stock worth $343,105,000 after purchasing an additional 405,611 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Incyte by 13.7% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,103,946 shares of the biopharmaceutical company’s stock valued at $263,246,000 after purchasing an additional 373,298 shares during the period. Morgan Stanley lifted its position in Incyte by 0.9% during the 4th quarter. Morgan Stanley now owns 2,663,823 shares of the biopharmaceutical company’s stock valued at $263,106,000 after purchasing an additional 23,087 shares during the period. Finally, Robeco Institutional Asset Management B.V. boosted its stake in shares of Incyte by 7.0% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 2,480,793 shares of the biopharmaceutical company’s stock valued at $245,028,000 after purchasing an additional 161,405 shares during the last quarter. 96.97% of the stock is owned by institutional investors.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte reported second-quarter revenue of $1.67 billion, up 37.7% year over year, while adjusted EPS of $3.09 exceeded the $2.20 analyst consensus. The results were driven by stronger product sales, particularly Jakafi and Opzelura. Incyte quarterly earnings report
• Positive Sentiment: Management raised 2026 total net-sales guidance to $5.13 billion-$5.26 billion, from $4.77 billion-$4.94 billion previously. Opzelura guidance was increased to $1.05 billion-$1.10 billion following a CMS-related settlement. Incyte 2026 sales guidance
• Positive Sentiment: Opzelura net sales surged 173% to $450 million, including a $246 million one-time, non-cash benefit related to the CMS agreement. Hematology and Oncology portfolio sales rose 69% to $222 million, supporting management’s view that Incyte is becoming less dependent on a single drug. Incyte second-quarter revenue growth
• Positive Sentiment: Investors also received a more visible catalyst pipeline, with Incyte expecting approximately ten clinical data readouts—including four registrational trials—in the second half of 2026. Incyte no longer a one-drug story

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.